摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-1-(3-ethoxyphenyl)ethanamine

中文名称
——
中文别名
——
英文名称
(R)-1-(3-ethoxyphenyl)ethanamine
英文别名
(1R)-1-(3-ethoxyphenyl)ethanamine
(R)-1-(3-ethoxyphenyl)ethanamine化学式
CAS
——
化学式
C10H15NO
mdl
——
分子量
165.23
InChiKey
YIPGPYIRKCOZJP-MRVPVSSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    (3R)-3-(6-fluoro-3-pyridyl)cyclopentanone 、 (R)-1-(3-ethoxyphenyl)ethanamine 生成 (1S,3R)-N-[(1R)-1-(3-ethoxyphenyl)ethyl]-3-(6-fluoro-3-pyridyl)cyclopentanamine
    参考文献:
    名称:
    SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS
    摘要:
    一般式I的化合物(公式[I]),它们作为钙受体活性化合物用于预防、治疗或改善与CaSR活性紊乱有关的生理障碍或疾病,例如甲状旁腺功能亢进症,包括该化合物的制药组合物以及使用该化合物治疗疾病的方法。
    公开号:
    US20130267516A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF<br/>[FR] NOUVEAUX COMPOSÉS MODULANT LE RÉCEPTEUR SENSIBLE AU CALCIUM, ET LEUR UTILISATION PHARMACEUTIQUE
    申请人:LEO PHARMA AS
    公开号:WO2010136037A1
    公开(公告)日:2010-12-02
    The invention relates to novel calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.
    该发明涉及一种表示为公式I的新型调节钙感受受体(CaSR)的取代环戊烯化合物及其衍生物,该化合物用作药物,用于治疗的化合物,包含该化合物的制药组合物,使用该化合物治疗疾病的方法以及使用该化合物制造药物。
  • [EN] SUBSTITUTED CYCLOPENTYL - AZINES AS CASR- ACTIVE COMPOUNDS<br/>[FR] CYCLOPENTYLAZINES SUBSTITUÉES EN TANT QUE COMPOSÉS CASR-ACTIFS
    申请人:LEO PHARMA AS
    公开号:WO2012069402A1
    公开(公告)日:2012-05-31
    Compounds of general formula I, (formula [I)], their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds.
    通用公式I的化合物,其用作钙受体活性化合物,用于预防、治疗或改善与CaSR活性紊乱相关的生理障碍或疾病,如甲状旁腺功能亢进症,包括所述化合物的药物组合物,以及使用所述化合物治疗疾病的方法。
  • COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES
    申请人:Swann Steven L.
    公开号:US20090258907A1
    公开(公告)日:2009-10-15
    Disclosed herein are compounds of formula (I) or pharmaceutical acceptable salts thereof, wherein X, R 1 , R 2 , R 3 , R 4 , L 1 , and m, are defined in the specification. Compositions comprising said compounds which can be useful for inhibiting Rho kinase (ROCK) and methods for using said compositions are also described.
    本文披露了公式(I)的化合物或其药物可接受的盐,其中X、R1、R2、R3、R4、L1和m在规范中定义。还描述了包含所述化合物的组合物,其可以用于抑制Rho激酶(ROCK),以及使用所述组合物的方法。
  • NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF
    申请人:Nørremark Bjarne
    公开号:US20120122784A1
    公开(公告)日:2012-05-17
    The invention relates to novel calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.
    该发明涉及一种新型的钙感受受体(CaSR)调节代替环戊烯化合物,其在式I中表示及其衍生物,以及将该化合物用作药物的方法,将该化合物用于治疗的方法,包含该化合物的制药组合物,使用该化合物治疗疾病的方法,以及将该化合物用于制造药物的用途。
  • CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS
    申请人:Vedsø Per
    公开号:US20130244995A1
    公开(公告)日:2013-09-19
    Compounds of general formula (I), their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds.
    通式(I)的化合物,它们作为钙受体活性化合物用于预防、治疗或改善与CaSR活性紊乱相关的生理障碍或疾病,例如甲状旁腺功能亢进症,包含该化合物的制药组合物,以及使用该化合物治疗疾病的方法。
查看更多